CLAIMS

1. Use of N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) or a derivative thereof dissolved in sterile water, buffer, saline or other pharmaceutically acceptable carriers; and

one or more optional excipients, diluents, extended or controlled release agents, coloring agents, preservatives or any combinations thereof

in the manufacture of a medicament for the treatment of withdrawal symptoms and pain associated with withdrawal of anti-depressants, selective serotonin inhibitors (SSRI) following treatment for a demyelination disease, a neuropsychiatric disorder wherein the symptoms are due to demyelination, or a post-chemotherapy cognitive impairment wherein the symptoms are due to demyelination.

2. The use of claim 1, wherein the HEPES is dissolved in sterile water for injection for oral, subcutaneous, parenteral, intravenous, peritoneal, or intramuscular administration.

3. The use of claim 1, wherein the once daily dose is based on a body weight at 10-100 mg/kg.

4. The use of claim 1, wherein the anti-depressants are selected from the group consisting of benzodiazepines, SSRIs, Serotonin-norepinephrine reuptake inhibitors (SNRIs), Noradrenergic and specific serotonergic antidepressants (NaSSAs), Norepinephrine (noradrenaline) reuptake inhibitors (NRIs), Norepinephrine-dopamine reuptake inhibitors (NDRIs), Selective serotonin reuptake enhancers (SSREs), Melatonergic agonists, Tricyclic antidepressants (TCAs), and Monoamine oxidase inhibitor (MAOIs).

5. The use of claim 1, wherein the SSRIs comprise citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, zimelidine or any combinations thereof.